Lilly's Olumiant gets new FDA approval, nabbing a landmark greenlight for autoimmune hair loss disease
Pfizer, Concert Pharmaceuticals and Eli Lilly were all gunning to be the first company to bring an alopecia areata drug to market. But Lilly crossed the finish line first Monday.
The Indianapolis-based pharma announced that FDA had approved JAK inhibitor baricitinib, aka Olumiant, for patients with severe forms of the autoimmune disorder alopecia areata (AA), which results in hair loss. The drug, which was approved as a once-daily pill in three dose levels of 1 mg, 2 mg and 4 mg for the indication, had been originally discovered by Incyte before Lilly in-licensed it back in 2009.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.